Levosimendan, a novel calcium sensitizer, enhances cardiac contractility by increasing myocyte sensitivity to calcium, and induces vasodilation. In this prospective observational study the haemodynamic effects of levosimendan in postoperative critically ill patients are reported. Twelve patients with the need for inotropic support were studied. One dose of levosimendan (12.5 mg) was administered at a rate of 0.1-0.2 µg.kg -1 .min -1 , either alone or in addition to pre-existing inotropic therapy. Haemodynamic measurements were obtained at baseline, and at 3 h, 6 h, 12 h, and 24 h after the start of the levosimendan infusion.
Positive inotropic agents play an important role in the short-term haemodynamic management of patients in the ICU. β-adrenergic agonists and phosphodiesterase inhibitors exert a positive inotropic action primarily by increasing cyclic adenosine monophosphate (cAMP) and calcium in cardiac myocytes. Although β-adrenergic agonists and phosphodiesterase inhibitors are effective positive inotropic agents, their use may be limited by several problems 1, 2, 3 . First, the increased intracellular calcium concentrations increase myocardial oxygen consumption and may enhance the risk of arrhythmias 3 . Second, due to desensitization of the β-adrenergic pathway, the positive inotropic effect is limited by tachyphylaxis. Third, while the short-term use of β-agonists and phosphodiesterase inhibitors improves haemodynamics in patients with heart failure, their effect on long-term outcome is unclear 1, 2 .
Increasing myocyte sensititivity to calcium is a new alternative basis for inotropic therapy. This approach has the theoretical advantage of enhancing contractile perfomance of the failing heart with little increase in total myocardial oxygen demand 4, 5 and with decreased potential for arrhythmias 6 . The novel calcium sensitizer, levosimendan, promotes inotropy by stabilizing troponin C in a configuration which enhances the calcium sensitivity of cardiac myofilaments 7 . In contrast to other calcium sensitizers, this effect of levosimendan is dependent on the concentration of intracellular ionized calcium. As a result, levosimendan has been shown to increase contractile force during systole, but not to impair ventricular relaxation. Levosimendan also leads to vasodilation through the opening of adenosine triphosphate (ATP)-sensitive potassium channels 8 .
Previous clinical trials have established the favourable haemodynamic effects of intravenously administered levosimendan in patients with moderate or severe heart failure [9] [10] [11] [12] and during cardiac surgery 5, 13 , but data on its use in postoperative critically ill patients is limited. Patients in the intensive care unit (ICU) following major surgery differ from patients admitted to the hospital with stable or decompensated heart failure. The inflammatory response to surgical trauma, catabolic illness, problems with wound healing and tissue repair, difficulties in weaning from the ventilator, infectious complications, and dysfunction in multiple organ systems can alter drug responses. Therefore, the efficacy of levosimendan has to be addressed in such a patient population. We report on our experience with levosimendan and on the observed haemodynamic changes in postoperative critically ill patients.
METHODS
The investigation was performed according to the principles of the Helsinki declaration and according to the guidelines of the local ethics committee. Postoperative patients in a critical haemodynamic state were considered as candidates for levosimendan administration. Patients received levosimendan for clinical reasons, if haemodynamic data, as assessed from a pulmonary artery catheter, indicated a need for inotropic support. Levosimendan was administered either alone or as an adjunct to existing inotropic therapy. The indication for treatment with levosimendan was at the discretion of the attending intensivist. Between October 2001 and November 2002 twelve postoperative ICU patients were studied. Nine patients had undergone cardiac surgery (coronary artery surgery/valve replacement), two had had lung transplantation, and one patient needed cardiopulmonary resuscitation after upper arm fracture repair. Their mean age was 69±9 years, mean body weight 73±11 kg and mean height 164±9 cm. At the time of investigation 10 patients were sedated and mechanically ventilated, two were extubated and breathing spontanously. Two patients were on an intra-aortic balloon pump during the study. At the time of investigation 10 patients were on inotropic support and received levosimendan as add-on therapy. Two patients received levosimendan without additional inotropes. One dose of levosimendan (12.5 mg) was administered at an infusion rate of 0.1-0.2 µg.kg -1. min -1 . No loading dose was given. Prior to the infusion of levosimendan, patients were fluid-loaded to optimize cardiac filling pressures. Preexisting infusions with dobutamine or milrinone were maintained at the same rate or were reduced if possible. A pre-existing infusion with adrenaline or noradrenaline was adjusted to keep mean arterial pres-sure (MAP) between 70 and 80 mmHg. Fluid management was tailored according to pulmonary capillary wedge pressure (PCWP) and MAP. Haemodynamic measurements were obtained at baseline, 3 h, 6 h, 12 h, and 24 h after the start of the levosimendan infusion.
Statistical analysis
All data are presented as mean± standard deviation. Changes in haemodynamic variables from baseline to 24 h were assessed using repeated measures analysis of variance. Differences between baseline and the 3 h, 6 h, 12 h, and 24 h data were determined by Student-Newman-Keuls test when necessary. A P value <0.05 was considered significant.
RESULTS
The haemodynamic effects of levosimendan are presented in Table 1 . Administration of levosimendan increased cardiac output (CO) by 21%. At baseline mean CO was 4.3±0.9 l.min -1 (cardiac index 2.3± 0.4 l.min -1 .m -2 ) and increased to 5.2±1.5 l.min -1 (cardiac index 2.8±0.6 l.min -1 .m -2 ) after 24 hours (P=0.013). The increase in CO was paralleled by a significant increase in stroke volume from 47±15 ml to 57±25 ml (P=0.05), while heart rate remained unchanged throughout the study (Figure 1a ). Levosimendan decreased systemic vascular resistance (SVR), from 1239±430 dyn.sec.cm -5 to 963±322 dyn.sec.cm -5 at 24 hours (P<0.001). Although MAP tended to decrease with reductions in SVR, this did not reach statistical significance (P=0.09) (Figure 1b) . The vasodilating effect of levosimendan on the pulmonary circulation was less pronounced than that on the systemic circulation. Pulmonary vascular resistance (PVR) was 281±112 dyn.sec.cm -5 at baseline and 217 ±99 dyn.sec.cm -5 after 24 h (P=0.09), but mean pulmonary artery pressure (PAP) remained unchanged (34±13 mmHg at baseline, 32±14 mmHg after 24 h, respectively). Central venous pressure and PCWP remained within a narrow range throughout the study (Table 1) .
At the time of inclusion in the study, prior to the commencement of levosimendan infusion, ten patients were on adrenaline and/or noradrenaline treatment, which was combined with dobutamine (n=3) or milrinone (n=3) in six. During the study there was no significant change in the total dose of the epinephrine/norepinephrine therapy. At baseline adrenaline/noradrenaline was infused at a rate of 0.33±0.39 µg.kg -1 .min -1 , at 12 h at a rate of 0.37± 0.43 µg.kg -1 .min -1 , and at 24h at a rate of 0.30± 0.37 µg.kg -1 .min -1 (P=0.47). In none of the patients who were on dobutamine or milrinone in addition to their adrenaline/noradrenaline therapy, did the infusion of dobutamine or milrinone have to be increased. During levosimendan treatment, the infusion rate of dobutamine was reduced by 50% in two patients and remained unchanged in one. Milrinone could be terminated in one patient and was maintained at the same level in the other two.
No clinically significant adverse events were observed during the study period.
DISCUSSION
This preliminary study demonstrates that levosimendan is haemodynamically effective in postoperative critically ill patients. Levosimendan caused a parallel increase in SV and CO, both of 21%, while heart rate remained unchanged. Levosimendan also caused arterial dilatation and decreased SVR by 32%. These findings are consistent with those of other studies 4,5,7-13 .
Although levosimendan did not induce changes in heart rate in our patients, increases in heart rate have been reported by others 5,10-13 . However, this effect of levosimendan appears to be dose-dependent. When administered as a bolus to patients shortly after cardiopulmonary bypass, levosimendan caused increases in CO with both doses, but heart rate increased only with the higher dose 5 . In patients undergoing cardiac surgery: levosimendan (loading dose 18 or 36 µg.kg -1 and 0.2 or 0.3 µg.kg -1 .min -1 infusion, respectively) or placebo was administered during and after cardiopulmonary bypass 13 . Both doses of levosimendan increased CO, but heart rate was greater in patients receiving high-but not low-dose levosimendan versus placebo 13 . Thus, it seems that an infusion of levosimendan at a low dose (0.1-0.2 µg.kg -1 .min -1 ), as was used in the present study, should not cause significant changes in heart rate.
In this study, the reductions in SVR were accompanied by modest decreases in MAP, although this did not reach statistical significance. Because the total dose of the adrenaline/noradrenaline infusion remained within a narrow range throughout the study, reductions in SVR were counteracted by increases in CO and resulted in only modest decreases in MAP. During levosimendan administration, decreases in MAP are known to be dose-dependent 9 , but the magnitude of the response may vary between patients. In contrast to other clinical studies 9,10,11 we maintained cardiac filling pressures by fluid administration. As such, venous vasodilation caused by levosimendan did not result in preload reductions. We did not begin treatment with levosimendan with a loading dose. We have observed in some surgical patients that a loading dose (0.24 µg.kg -1 over 10 min), results in a rapid fall in SVR and MAP. As levosimendan has an active metabolite with a 72-hour half-life, a severe reduction in SVR may be prolonged and might require vasopressor therapy. Without giving a loading dose, significant haemodynamic responses were achieved within 6 h, by a continuous levosimendan infusion of 0.1-0.2 µg.kg -1 .min -1 , while the maximum effects were seen after 12 h and 24 h. Importantly, levosimendan proved to be effective during concomitant catecholamine therapy. Ten patients were on intravenous inotropic therapy prior to the commencement of levosimendan. Levosimendan was administered in addition to catecholamines (adrenaline and noradrenaline), β-adrenergic agonists (dobutamine), and phosphodiesterase inhibitors (milrinone). Because levosimendan acts via a cAMP independent pathway 7 as an adjunct to standard inotropic therapy. Unlike all other currently available intravenous inotropic agents, levosimendan exerts its action without increasing intracellular cAMP and calcium. As such, combining the calcium sensitizing properties of levosimendan with agents increasing intracellular calcium might exert supra-additive effects. This could, in turn, improve cardiovascular haemodynamics in otherwise unresponsive patients. However, further studies are necessary to investigate the effects of levosimendan in combination with other inotropic agents. These results must be interpreted within the constraints of several limitations. Firstly, although the increase in CO and SV might be attributed primarily to the inotropic properties of the drug, it is possible that some of the increase in SV reflected a decrease in left ventricular afterload. Secondly, due to the uncontrolled nature of the present series, we cannot comment on time-dependent physiological changes that may have contributed to the observed alterations in haemodynamic parameters. However, we believe that the substantial haemodynamic changes cannot be explained by the natural time related course because significant haemodynamic responses were seen within 6 h of treatment with levosimendan, suggesting a direct drug effect. Thirdly, the concomitant use of other vasoactive drugs may have also influenced the observed effects.
In conclusion, in postoperative critically ill patients, infusion of levosimendan appeared to exert favourable haemodynamic responses. Levosimendan increased cardiac output by increases in stroke volume. Due to its cAMP independent positive inotropic effects, levosimendan might be of value as adjunctive therapy to other inotropic drugs in critically ill patients. However, due to the preliminary nature of these data further studies are necessary to evaluate the use of levosimendan in postoperative critically ill patients.
